[go: up one dir, main page]

MX2013001124A - Metodos para tratar y/o revertir enfermedades y/o transtornoss neurodegenerativos. - Google Patents

Metodos para tratar y/o revertir enfermedades y/o transtornoss neurodegenerativos.

Info

Publication number
MX2013001124A
MX2013001124A MX2013001124A MX2013001124A MX2013001124A MX 2013001124 A MX2013001124 A MX 2013001124A MX 2013001124 A MX2013001124 A MX 2013001124A MX 2013001124 A MX2013001124 A MX 2013001124A MX 2013001124 A MX2013001124 A MX 2013001124A
Authority
MX
Mexico
Prior art keywords
methods
disorders
brain
treating
neurodegenerative diseases
Prior art date
Application number
MX2013001124A
Other languages
English (en)
Other versions
MX341316B (es
Inventor
Woei-Cherng Shyu
Shinn-Zong Lin
Hsiao-Jung Wang
Karl K Johe
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of MX2013001124A publication Critical patent/MX2013001124A/es
Publication of MX341316B publication Critical patent/MX341316B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)

Abstract

La presente descripción proporciona métodos para el tratamiento de enfermedades/trastornos neurológicos utilizando células madre neurales (NSCs) obtenidas de un tejido de médula espinal. Los métodos pueden incluir el uso de una población de NSC para tratar una enfermedad/trastorno neurológico del cerebro. Dichos métodos pueden incluir introducir NSCs exógenamente cultivadas y expandidas en el cerebro, las cuales diferencian en neuronas capaces de integración in vivo en el tejido cerebral en una forma suficiente para mejorar los síntomas asociados con la enfermedad/ trastorno neurológico.
MX2013001124A 2010-07-28 2011-07-28 Poblacion de celulas madre neurales para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos. MX341316B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36840910P 2010-07-28 2010-07-28
PCT/US2011/045732 WO2012016049A1 (en) 2010-07-28 2011-07-28 Methods for treating and/or reversing neurodegenerative diseases and/or disorders

Publications (2)

Publication Number Publication Date
MX2013001124A true MX2013001124A (es) 2013-08-01
MX341316B MX341316B (es) 2016-08-15

Family

ID=44630526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001124A MX341316B (es) 2010-07-28 2011-07-28 Poblacion de celulas madre neurales para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos.

Country Status (16)

Country Link
US (1) US9540611B2 (es)
EP (1) EP2598154B1 (es)
JP (2) JP6077996B2 (es)
KR (1) KR101765980B1 (es)
CN (1) CN103237553A (es)
AU (1) AU2011282642B2 (es)
CA (1) CA2806904C (es)
ES (1) ES2571991T3 (es)
IL (1) IL224416A (es)
MX (1) MX341316B (es)
MY (1) MY168084A (es)
NZ (2) NZ607195A (es)
RU (1) RU2013108868A (es)
SG (1) SG187226A1 (es)
WO (1) WO2012016049A1 (es)
ZA (1) ZA201300954B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055685A2 (en) * 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US9072678B2 (en) 2013-03-14 2015-07-07 Pathak Holdings Llc Methods for local drug delivery by microinjection
US10624865B2 (en) 2013-03-14 2020-04-21 Pathak Holdings Llc Methods, compositions, and devices for drug/live cell microarrays
US9789073B2 (en) 2013-03-14 2017-10-17 Pathak Holdings, Llc Compositions, methods and devices for local drug delivery
WO2014160387A2 (en) * 2013-03-14 2014-10-02 Pathak Holdings, Llc Compositions, methods and devices for local drug delivery
WO2015006474A1 (en) * 2013-07-09 2015-01-15 Neuralstem, Inc. Methods of treating a subject with a cognitive dysfunction using spinal cord-derived neural stem cells
US10947500B2 (en) 2014-06-27 2021-03-16 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
EP3334414A4 (en) * 2015-08-15 2019-03-20 Asterias Biotherapeutics, Inc. OLIGODY DROCYTE STEM CELL PREPARATION CELLS FOR THE TREATMENT OF WHITE STROKE
CN106619722A (zh) * 2016-12-05 2017-05-10 上海安集协康生物技术股份有限公司 一种治疗脑部损伤类疾病的神经干细胞注射液
CN115089613A (zh) * 2022-07-25 2022-09-23 朗姿赛尔生物科技（广州）有限公司 一种神经干细胞移植在神经退行性疾病中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4753635A (en) 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
NZ226750A (en) 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
AU623922B2 (en) 1988-08-04 1992-05-28 Amrad Operations Pty. Limited In vitro propagation of embryonic stem cells
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4980174A (en) 1988-12-23 1990-12-25 Jacqueline Sagen Method for alleviating depression
WO1991002003A1 (en) 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
WO1991009936A1 (en) 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
US5196315A (en) 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
JP4416837B2 (ja) 1991-07-08 2010-02-17 ニューロスフィアーズ ホウルディングス リミテッド 試験管内で増殖し得る新規な成長因子応答性の前駆細胞
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5175103A (en) 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
CA2122058C (en) 1991-11-22 2001-07-31 Peter Gluckman Tgf-beta to improve neural outcome
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
AU678988B2 (en) 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
AU4995193A (en) 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994004675A2 (en) 1992-08-19 1994-03-03 Richard Kroczek Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
ATE234353T1 (de) 1992-10-28 2003-03-15 Neurospheres Holdings Ltd Biologische faktoren und neuronale stammzellen
CN1141058A (zh) 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 中枢神经系统干细胞的原位修饰和处理
DK0783693T3 (da) 1994-09-23 2002-01-14 Neurospheres Holdings Ltd In vitro-modeller for CNS-funktion og -dysfunktion
KR970707272A (ko) 1994-11-14 1997-12-01 스코트 디. 코르맥 신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation)
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU7258098A (en) 1997-04-24 1998-11-13 California Institute Of Technology Methods for differentiating neural stem cells
CA2294737A1 (en) 1997-07-04 1999-01-14 University Of Utah Research Foundation Neuron-restricted precursor cells
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5932473A (en) 1997-09-30 1999-08-03 Becton Dickinson And Company Preparation of a cell culture substrate coated with poly-D-lysine
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
EP1115841B1 (en) 1998-09-22 2016-05-18 Neuralstem, Inc. Stable neural stem cell lines
US6284539B1 (en) 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
DE60217090T2 (de) 2001-04-23 2007-07-12 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
WO2003000852A2 (en) * 2001-06-22 2003-01-03 The University Of Texas System Method of producing region-specific neurons from human neuronal stem cells
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2006055685A2 (en) * 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
WO2008002250A1 (en) * 2006-06-30 2008-01-03 Elena Kozlova Improved stem cells for transplantation and methods for production thereof

Also Published As

Publication number Publication date
WO2012016049A1 (en) 2012-02-02
ZA201300954B (en) 2014-04-30
NZ623207A (en) 2014-12-24
AU2011282642A1 (en) 2013-03-07
JP2013532690A (ja) 2013-08-19
EP2598154A1 (en) 2013-06-05
MY168084A (en) 2018-10-11
EP2598154B1 (en) 2016-03-23
JP2015214589A (ja) 2015-12-03
AU2011282642B2 (en) 2015-06-11
KR101765980B1 (ko) 2017-08-07
SG187226A1 (en) 2013-03-28
CA2806904A1 (en) 2012-02-02
CN103237553A (zh) 2013-08-07
KR20140048064A (ko) 2014-04-23
ES2571991T3 (es) 2016-05-27
MX341316B (es) 2016-08-15
NZ607195A (en) 2014-08-29
IL224416A (en) 2017-06-29
JP6077996B2 (ja) 2017-02-08
RU2013108868A (ru) 2014-09-10
US20120177612A1 (en) 2012-07-12
CA2806904C (en) 2018-11-27
US9540611B2 (en) 2017-01-10

Similar Documents

Publication Publication Date Title
MY168084A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
PH12015501195A1 (en) Transplantation of human neural cells for treatment of neurodegenerative conditions
MX2012005131A (es) Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer.
MX2024014448A (es) Composiciones y metodos para enfermedades neurologicas
WO2011150005A3 (en) Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MX2011007578A (es) Metodos para diagnosticar y tratar la disfagia.
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
MY159562A (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
WO2010093904A9 (en) Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
MX2011007567A (es) Metodos para la inhibicion de la neurodegeneracion.
HK1215358A1 (zh) 由人多能幹細胞衍生的神經細胞在治療神經退行性疾病上的用途
WO2012024478A3 (en) Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
WO2010148065A3 (en) Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
WO2015191934A8 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
WO2011146675A3 (en) Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
WO2012040727A3 (en) Methods for diagnosis and treatment of neurodegenerative diseases or disorders
SG11201809512TA (en) Synapse formation agent

Legal Events

Date Code Title Description
FG Grant or registration